Page 7 - Weight Loss

Learn about the common and rare side effects of Wegovy 7.2 mg, the new higher-dose semaglutide for weight loss. Understand safety, risks, and monitoring.

Clinical trials show Wegovy 7.2 mg helps patients lose up to 21% body weight in 72 weeks. Learn how it compares to 2.4 mg and what to expect in the UK.

Wegovy 7.2 mg may help patients who’ve plateaued on lower doses. Learn who qualifies, when it’s coming to the UK, and how it fits into treatment plans.

Wegovy 7.2 mg is a higher-dose semaglutide for people who’ve reached a plateau on 2.4 mg. Learn who’s eligible, safety guidance, and UK approval status.

Discover how Mounjaro may support heart health beyond weight loss, with potential benefits for blood pressure, cholesterol, and cardiovascular wellbeing.

Thinking about restarting GLP-1 injections? Learn who may be eligible, dose adjustment needs, and what to expect when restarting GLP-1 treatment safely.

Learn how Mounjaro may affect your menstrual cycle. Understand possible period changes on GLP-1 medications and when to seek expert advice.

Embarking on a weight loss journey with Mounjaro, a promising medication in the realm of obesity management, is an exciting step toward achieving your health goals. But what role do dietary and lifestyle changes play alongside this innovative medication? In this blog, we'll explore the potential benefits of incorporating such changes into your routine while taking Mounjaro, also known as tirzepatide.

Discover how Wegovy supports weight loss and heart health. Learn why semaglutide may offer better heart protection than other GLP-1 medicines.

Explore if Mounjaro is still worth it after the 2025 price spike. Compare costs, results, and alternatives in weight loss medications for UK patients.